US Patent 12,076,319 Landscape: Scope, Claims, and Expiration Drivers for PNH Treatment Using Oral “Compound 1” Plus Anti-C5 Monoclonal Antibodies
US Patent 12,076,319 claims combination methods for treating paroxysmal nocturnal hemoglobinuria (PNH) using an oral “Compound 1” administered with an anti-C5 monoclonal antibody (explicitly covering eculizumab and ALXN1210), with the patient selection keyed to extravascular and/or residual intravascular hemolysis, plus lab thresholds (notably hemoglobin <10 g/dL and LDH cutoffs).
Because the patent number and claim set are provided without the specification, dependent-claim numbering context, priority data, prosecution history, assignee, related family members, and the identity/structure of “Compound 1” are not provided. A complete, accurate landscape that ties scope of claims to the actual chemical claims in the specification, maps the full US family, and sets hard expiration/achievable exclusivity windows cannot be produced.
If sufficient bibliographic and family data are available in the record, the landscape below would be completed with exact expiration and terminal-disclaimer effects; as provided, the analysis is limited to claim-scope and enforceability vectors that are directly supported by the text of the claims alone.
What does US Patent 12,076,319 claim: method-of-treatment scope for PNH with oral Compound 1 + anti-C5 mAbs?
Core independent claim concept: A method for treating PNH in a human who has extravascular hemolysis at first dosing, comprising:
- Administering an anti-C5 monoclonal antibody in a therapeutically effective amount; and
- Administering “Compound 1” orally in a therapeutically effective amount; and
- Assigning combination timing condition: at the time of first Compound 1 administration, the patient is experiencing extravascular hemolysis.
(Claim 1)
Key dependent claim refinements in the dataset:
- Baseline anemia requirement: “has anemia” at time of first Compound 1 (Claim 2).
- Hemoglobin thresholding: Hgb < ~10 g/dL (Claim 3; also claim 6/11/15/16).
- Prior anti-C5 exposure: patient has been receiving a C5 inhibitor for at least three months, specifically that it is an anti-C5 monoclonal antibody (Claim 4 and multiple dependents).
- Hemolysis phenotype split:
- Extravascular hemolysis (Claim 1; and Claim 5 formulation includes that phenotype).
- Residual intravascular hemolysis despite ongoing regimen (Claim 10).
- Biomarker thresholds for LDH:
- LDH < ~250 U/L (Claim 7; also claim 18), and
- LDH > 250 U/L (Claim 12; also claim 17).
- Transfusion exposure: one or more blood transfusions within 12 months prior to first Compound 1 (Claim 8; also claim 13; claim 19).
- Anti-C5 monoclonal antibody identity limitation:
- eculizumab or ALXN1210 (Claims 21-24, and mirrored in the earlier dependents).
What patient state conditions narrow infringement risk?
The claims are not merely “PNH + oral drug + anti-C5.” They add phenotype and baseline status requirements that can materially affect enforceability and design-around:
- Extravascular hemolysis at first dosing is a condition for Claims 1 and 5-type methods.
- Residual intravascular hemolysis at first dosing is a distinct condition for Claims 10-type methods.
- Biomarker gating:
- Hemoglobin: <10 g/dL (multiple claims) and <8 g/dL (Claim 16).
- LDH: <250 or >250 depending on the dependent.
- Prior-treatment duration: at least 3 months on an anti-C5 monoclonal antibody (Claim 4 and others).
- Transfusion history within 12 months (Claims 8/13/19).
For infringement, the patent’s method steps require the clinician’s regimen to match the patient selection criteria at the time of first oral dosing.
How broad is “Compound 1” in the claim text provided?
The claims reference a structure in the claim (“Compound 1, which has the structure: …”), but the structure is not reproduced in the user input (it appears as a placeholder). Without the drawn structure, you cannot map:
- whether “Compound 1” is a known complement-related small molecule,
- whether there is a broader genus claim in the specification,
- or whether claim scope can extend to salts, stereoisomers, polymorphs, or prodrugs beyond what is explicitly stated.
The claim language provided does include pharmaceutically acceptable salts of Compound 1.
Which anti-C5 monoclonal antibodies are explicitly covered: eculizumab and ALXN1210?
The claim set explicitly limits the anti-C5 monoclonal antibody to:
- eculizumab or ALXN1210 (Claims 21-24; also embedded as the anti-C5 identity for dependent claims 2/6/10/15).
The independent claims (1, 5, 10, 15) are written around an anti-C5 monoclonal antibody without naming the specific product, but the scope of explicit claim coverage you provided crystallizes at least for eculizumab and ALXN1210. In practice, this can be important for both:
- licensing negotiations (which existing C5 mAb partners you can point to), and
- Paragraph IV-style design-around (if a challenger argues non-covered anti-C5 antibody types, to the extent claim construction permits).
When does US Patent 12,076,319 lose exclusivity: what expiration and exclusivity drivers control?
Not determinable from the provided information. A proper exclusivity timeline depends on:
- priority date(s),
- filing dates,
- patent term adjustments,
- terminal disclaimers,
- and whether any Orange Book-listed drug is tied to the patent (method patents can still be listed, but that linkage is not provided here).
What can be stated from the claim scope alone: The patent is a US utility method-of-treatment patent with claims tied to specific clinical states and combination regimens. Such patents typically fall under standard US utility term rules, but exact dates require bibliographic data.
No additional expiration statement can be made without an accurate record extract.
How many claims in US 12,076,319 materially narrow infringement to specific PNH biomarker phenotypes?
From the claim text provided, the following dependent-claim families narrow patient selection and thus can limit infringement exposure:
Extravascular hemolysis lane (Claims 1 and 5)
- anemia requirement (Claim 2)
- Hgb thresholds (Claim 3; and mirrored in Claim 6)
- C5 inhibitor duration and identity (Claim 4; Claims 9)
- LDH and transfusion features appear in the Claim 5 lane (Claims 7 and 8)
Residual intravascular hemolysis lane (Claims 10 and 15)
- Hgb thresholds (Claims 11 and 15; plus tighter thresholds at 8 g/dL in Claim 16)
- LDH cutoffs (Claims 12 and 17; plus the alternative LDH <250 in Claim 18)
- transfusion history (Claims 13 and 19)
- prior anti-C5 duration and identity (Claim 14 and Claim 20)
Discrete “identity” dependents
- anti-C5 mAb explicitly named as eculizumab or ALXN1210 (Claims 21-24)
Net effect: Even if an infringer uses an anti-C5 mAb plus an oral “Compound 1,” infringement can be avoided if the patient selection criteria are not met (or are not evidenced in a way that satisfies claim construction and burden of proof).
What formulations are protected: is the oral dosing form itself claimed, or only the combination method?
The claim text indicates:
- oral administration of Compound 1 (Claims 5, 10, 15; and Claim 1 via combination administration language),
- a requirement that Compound 1 is administered orally in a therapeutically effective amount,
- and coverage for pharmaceutically acceptable salts.
What is not shown in the provided excerpt:
- whether tablet/capsule/suspension forms are claimed,
- any specific formulation excipients,
- any controlled-release or pharmacokinetic parameters,
- any solid-state forms.
So based on the claim text provided, the protected subject matter is primarily method-of-treatment, with route of administration as an element (oral), and salt form as an allowed variant.
What method-of-use coverage exists beyond “PNH + anti-C5”?
US 12,076,319 is not a “broad regimen” claim on its own; it appears to be designed around:
- combination with prior complement inhibition (at least three months on an anti-C5 mAb),
- residual or ongoing hemolysis phenotype at the time the oral agent begins,
- and objective biomarker gatekeeping (Hgb and LDH) plus transfusion history.
That creates a recognizable patent strategy:
- protect incremental benefit or mechanistic differentiation (oral agent added to C5 blockade) in patients with persistent hematologic dysfunction,
- rather than simply protect the initial line of therapy for all-comers.
How strong is the patent estate for US 12,076,319: scope, claim quality, and litigation posture indicators?
A strength assessment cannot be complete without:
- the specification’s support for the “Compound 1” chemical identity,
- prosecution history (to check narrowing amendments),
- whether claims are likely obviousness-sensitive (based on prior art about combining oral agents with C5 mAbs),
- and whether the phenotype criteria are supported with experimental data.
From the provided claim set only, enforceability drivers include:
Strength factors
- The claims require multiple specific elements:
- anti-C5 monoclonal antibody,
- oral administration of Compound 1,
- presence of a hemolysis phenotype (extravascular or residual intravascular) at the time of first dosing,
- and additional gatekeeping for certain dependents (Hgb/LDH/transfusion/prior anti-C5 duration).
- Phenotype and biomarker criteria can support argument that the claim targets a specific clinical subgroup.
Vulnerability factors
- Method claims with clinical criteria can be attacked on:
- indefiniteness (how “experiencing extravascular hemolysis” is established),
- lack of enablement if the specification does not teach how to identify and treat the phenotype,
- and obviousness if prior art already discloses adding an oral agent to ongoing C5 mAb therapy in similar patient states.
- The claim text contains internal redundancies (for example, multiple LDH and hemoglobin threshold dependents). That can be fine, but it often signals careful claim crafting that could still be undermined by prior disclosures.
No net strength score is appropriate without file history and prior art mapping.
What generic entry risks exist for the oral Compound 1 + anti-C5 combination?
If “Compound 1” is itself a small molecule with generic pathways, the risk is typically assessed at three levels:
- whether generics can market Compound 1 alone (likely unaffected by method patents if they do not induce the claimed combination method),
- whether generics can sell a label that avoids the claimed method-of-use,
- whether the generic challenger’s clinical trial design and prescribing information can avoid meeting the phenotype criteria and duration criteria.
However, the claim set is method-oriented and includes:
- patient state at first dosing,
- prior anti-C5 regimen duration (three months),
- and transfusion/bio-marker thresholds for dependent claims.
That means a generic manufacturer’s main risk is not the chemical identity alone; it is whether commercial activity (promotion and label) would induce infringement of a method-of-use claim.
A definitive assessment requires Orange Book status, labeling, and litigation documents, none provided.
Does US 12,076,319 protect residual intravascular hemolysis patients differently than extravascular hemolysis patients?
Yes. The claim set distinguishes two conceptual subgroups:
- Claims 1 and 5: extravascular hemolysis at initiation of Compound 1.
- Claims 10 and 15: residual intravascular hemolysis at initiation of Compound 1.
This distinction matters because a challenger can attempt to avoid infringement by changing the timing or by treating a different hemolysis phenotype (or by arguing that the patient did not satisfy the claimed phenotype at initiation).
Dependent biomarker thresholds then refine these lanes:
- residual intravascular hemolysis includes explicit LDH directions in Claims 12 and 17/18,
- extravascular hemolysis includes LDH <250 (Claim 7) in the provided subset.
Key Takeaways
- US 12,076,319 is a method-of-treatment patent for PNH, combining oral “Compound 1” with an anti-C5 monoclonal antibody.
- The claims narrow infringement using patient hemolysis phenotype at initiation: extravascular hemolysis (Claims 1/5) versus residual intravascular hemolysis (Claims 10/15).
- Dependent claims further restrict by prior anti-C5 duration (≥3 months), biomarkers (Hgb <10 g/dL, Hgb <8 g/dL, LDH <250 or >250), and transfusion history.
- The anti-C5 monoclonal antibodies explicitly named include eculizumab and ALXN1210.
- Hard exclusivity dates, Orange Book listing status, and full family mapping require bibliographic record fields not provided; those cannot be stated accurately.
FAQs
- Do US 12,076,319 claims cover oral Compound 1 used with a C5 inhibitor that is not an anti-C5 monoclonal antibody?
- Can infringement occur if Compound 1 is administered orally but the anti-C5 antibody was stopped less than three months prior?
- How do the hemoglobin and LDH thresholds affect claim scope across the extravascular versus residual intravascular hemolysis lanes?
- Is transfusion history a strict element for all claims or only for dependent claims within US 12,076,319?
- Does the patent protect salts of Compound 1, and does it specify any particular oral dosage form?
References
No sources cited.
